Jpmorgan Chase & CO Pep Gen Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PEPG
# of Institutions
60Shares Held
25.2MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA10.7MShares$38.8 Million1.27% of portfolio
-
Janus Henderson Group PLC London, X02.34MShares$8.48 Million0.01% of portfolio
-
Suvretta Capital Management, LLC New York, NY1.66MShares$6.03 Million0.56% of portfolio
-
Viking Global Investors LP1.48MShares$5.38 Million0.05% of portfolio
-
Perceptive Advisors LLC New York, NY1.41MShares$5.12 Million0.32% of portfolio
About PepGen Inc.
- Ticker PEPG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,631,900
- Market Cap $85.8M
- Description
- PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...